Allovir Inc (ALVR) USD0.0001

Sell:$9.59Buy:$9.98$0.11 (1.13%)

Prices delayed by at least 15 minutes
Sell:$9.59
Buy:$9.98
Change:$0.11 (1.13%)
Prices delayed by at least 15 minutes
Sell:$9.59
Buy:$9.98
Change:$0.11 (1.13%)
Prices delayed by at least 15 minutes

Company Information

About this company

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Key people

David L. Hallal
Executive Chairman of the Board
Vikas Sinha
President, Chief Executive Officer, Chief Financial Officer, Director
Ann Leen
Co-Founder, Chief Scientific Officer
Brett R. Hagen
Chief Accounting Officer
Edward Miller
General Counsel, Secretary
Juan F. Vera
Director, Co-Founder
Derek Adams
Independent Director
Jeffrey S. Bornstein
Independent Director
Malcolm Brenner
Independent Director, Co-Founder
Morana Jovan-Embiricos
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0198182026
  • Market cap
    $49.31m
  • Employees
    112
  • Shares in issue
    5.04m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.